Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study

Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study

Objectives: Guselkumab, an interleukin-23 antagonist, is approved for self-administration with the UltraSafe Plus™ syringe to treat moderate-to-severe plaque-type psoriasis. We evaluated the efficacy, safety, pharmacokinetics, and acceptability of guselkumab administered using a novel patient-contro...

Full description

Bibliographic Details
Main Authors: Laura K. Ferris, Elyssa Ott, Jingzhi Jiang, H. Chih-Ho Hong, Shu Li, Chenglong Han, Wojciech Baran
Format: Article
Language:English
Published: Taylor & Francis Group 2020-02-01
Series:Journal of Dermatological Treatment
Subjects:
acceptability
interleukin-23
psoriasis
self-injector
siaq
Online Access:http://dx.doi.org/10.1080/09546634.2019.1587145

Internet

http://dx.doi.org/10.1080/09546634.2019.1587145

Similar Items